Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.

The Eastern Cooperative Oncology Group (ECOG) trial of adjuvant cyclophosphamide, methotrexate, fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen (CMFPT) for 1 year compared with observation alone in 265 postmenopausal patients with node-positive breast cancer is reported with 74 months median follow-up. Overall relapse-free survival tended to favor CMFPT (P = .08), but no survival differences existed between any treatment group. The addition of tamoxifen to CMFP led to slightly (but not significantly) better relapse-free status in all subgroups analyzed. Subgroup analysis based on stratification variables showed significant benefit from CMFP (+/- T) only in estrogen receptor (ER)-negative patients with respect to disease-free status (P = .0003), but not survival (P = .54). Relapse-free status was actually worse for CMFP-treated patients with ER-positive tumors, but not significantly so (P = .15). By multivariate analysis other significant risk factors for relapse-free status were primary tumor size, number of nodes pathologically involved, and the number of nodes examined. ER status was prognostic only for the observation group with the benefit from chemotherapy on ER-negative patients obliterating this difference in treated patients. Survival was affected by the number of involved nodes, tumor size, presence of tumor necrosis, and patient obesity. Analysis of toxicity showed elevation of liver enzymes during the first year to be more common in the observation group compared with those patients receiving adjuvant treatment and to be associated with early recurrence. Toxicity from adjuvant treatment persisted beyond termination of therapy in 53% of patients, but was usually mild and self-limited. We conclude CMFPT offers relapse-free survival benefit in ER-negative patients, but the value of chemotherapy in ER-positive postmenopausal, node-positive patients must be questioned.

[1]  C K Osborne,et al.  Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.

[2]  R. Gelber,et al.  A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Gelber,et al.  Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials. , 1986, JAMA.

[4]  C. Osborne,et al.  Adjuvant therapy of breast cancer: Southwest Oncology Group studies. , 1986, NCI monographs : a publication of the National Cancer Institute.

[5]  R. Gelber,et al.  Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. , 1986, NCI monographs : a publication of the National Cancer Institute.

[6]  H. Mouridsen,et al.  Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials. , 1986, NCI monographs : a publication of the National Cancer Institute.

[7]  G. Ribeiro,et al.  The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma--7-yr results. , 1985, European journal of cancer & clinical oncology.

[8]  L. Kalish,et al.  Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Crowe,et al.  Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up. , 1984, Surgery.

[10]  Nitin R. Patel,et al.  A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .

[11]  G. Bonadonna,et al.  Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[13]  P. Band,et al.  Comparison of induction chemotherapies for metastatic breast cancer. An eastern cooperative oncology group trial , 1982, Cancer.

[14]  G. Bonadonna,et al.  Multimodal treatment in operable breast cancer: five-year results of the CMF programme. , 1981, British medical journal.

[15]  T. Powles,et al.  ASSESSMENT OF BIOCHEMICAL TESTS TO SCREEN FOR METASTASES IN PATIENTS WITH BREAST CANCER , 1980, The Lancet.

[16]  S. Lagakos,et al.  Sample size and power determination for stratified clinical trials , 1978 .

[17]  E. Lehmann,et al.  Nonparametrics: Statistical Methods Based on Ranks , 1976 .

[18]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[19]  D. Cox.  Regression Models and Life-Tables , 1972 .